$143.04
4.70% today
Nasdaq, Apr 04, 09:47 pm CET
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Ascendis Pharma A/S Sponsored ADR Stock price

$150.09
-1.84 1.21% 1M
+9.14 6.48% 6M
+12.42 9.02% YTD
+0.59 0.39% 1Y
+32.69 27.85% 3Y
+38.09 34.01% 5Y
+132.70 763.08% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-2.06 1.35%
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Key metrics

Market capitalization $8.98b
Enterprise Value $9.29b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 23.71
P/S ratio (TTM) P/S ratio 22.92
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 36.09%
Revenue (TTM) Revenue $391.88m
EBIT (operating result TTM) EBIT $-302.66m
Free Cash Flow (TTM) Free Cash Flow $-334.56m
Cash position $579.41m
EPS (TTM) EPS $-7.13
P/E forward negative
P/S forward 14.62
EV/Sales forward 15.12
Short interest 8.78%
Show more

Is Ascendis Pharma A/S Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Ascendis Pharma A/S Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

Buy
94%
Hold
6%

Financial data from Ascendis Pharma A/S Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
392 392
36% 36%
100%
- Direct Costs 61 61
10% 10%
16%
330 330
51% 51%
84%
- Selling and Administrative Expenses 290 290
18% 18%
74%
- Research and Development Expense 324 324
28% 28%
83%
-284 -284
40% 40%
-72%
- Depreciation and Amortization 19 19
6% 6%
5%
EBIT (Operating Income) EBIT -303 -303
39% 39%
-77%
Net Profit -410 -410
21% 21%
-105%

In millions USD.

Don't miss a Thing! We will send you all news about Ascendis Pharma A/S Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ascendis Pharma A/S Sponsored ADR Stock News

Neutral
GlobeNewsWire
4 days ago
—  Data demonstrated multiple clinical benefits beyond linear growth —  NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years of open-label extension data —  MAA in EU on track for submission during Q3 2025 COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) tod...
Neutral
GlobeNewsWire
about one month ago
COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
Neutral
Seeking Alpha
about 2 months ago
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Everc...
More Ascendis Pharma A/S Sponsored ADR News

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Head office Denmark
CEO Jan Mikkelsen
Founded 2006
Website www.ascendispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today